| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| ln Vitro |
MT-125 free base (5 μM, 8 h) significantly inhibited the invasive ability of one mouse (MES1861) and three human (187, 190 and L1) GBM cell lines[1]. MT-125 free base (5 μM, 48 h) caused 12%–25% cell multinucleation in 10 human GBM cell lines[1]. MT-125 free base (0.1–10 μM; 96 h) produced more than 90% cytotoxicity in various mouse and human GBM cell lines[1]. MT-125 increased reactive oxygen species (ROS) and lipid peroxidation levels in L1 cells[1]. MT-125 free base (4 μM) induced ferroptosis in Trp53(-/-) cells, and its cytotoxicity was reversed by ferroptosis inhibitors[1]. MT-125 free base (5 μM, 48 h) significantly increased PDGFRα expression and activation of downstream signaling pathways in Trp53(-/-) cells [1]. MT-125 free base (5 μM, 48 h) regulated the MAPK signaling pathway in Trp53(-/-) cells by inhibiting NMIIA [1]. MT-125 free base (5 μM, 48 h) showed synergistic effects with oncogenic kinase inhibitors in Trp53(-/-) cells [1].
|
|---|---|
| ln Vivo |
MT-125 free base (10 mg/kg; subcutaneous injection; once daily for 2 weeks) showed low toxicity in C57BL/6 mice[1]. MT-125 free base (20 mg/kg, subcutaneous injection; once daily for 7 days) did not cause any drug-related adverse reactions or affect age-related weight changes in C57BL/6 mice[1]. (7.5, 15 or 30 mg/kg; subcutaneous injection; once daily for 28 days) remained well-tolerated in female-associated repeated-dose toxicology studies[1]. MT-125 free base (10 mg/kg; intraperitoneal injection; once daily for 4 weeks) had a significant effect on tumor cell growth in C57BL/6 tumor blastoma and could significantly inhibit tumor cell growth[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: murine (TRP53(-/-), Pten(-/-), TRP53/Pten(-/-)) and human (L1, L0, GBM1A, 612, QNS120, QNS166, QNS315) GBM cell lines Tested Concentrations: 3.3-7.3 μM Incubation Duration: 96 h Experimental Results: Significantly inhibited the GBM cell lines. Western Blot Analysis[1] Cell Types: Trp53(‒/‒) cells Tested Concentrations: 5 μM Incubation Duration: 48 h Experimental Results: Effectively enhanced activation of PDGFRα, AKT, mTOR, ERK1/2, and SRC. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice (8-10 weeks; 25-35 g)[1]
Doses: 10 mg/kg Route of Administration: Subcutaneous injection (s.c.); once daily for 2 weeks Experimental Results: Had good tolerance and the weight and hematological indicators of mice were within normal range. Animal/Disease Models: C57BL/6 mice (8-10 weeks; 25-35 g)[1] Doses: 20 mg/kg Route of Administration: Subcutaneous injection (s.c.); once daily for 7 days Experimental Results: Maintained normal body weight and hematological parameters within the normal range in mice. Animal/Disease Models: Female rats (8-10 weeks; 25-35 g)[1] Doses: 7.5, 15, or 30 mg/kg Route of Administration: Subcutaneous injection (s.c.); once daily for 28 days Experimental Results: Did not cause any obvious or lasting adverse health effects. Animal/Disease Models: C57BL/6 mice with Trp53(‒/‒) tumors (8-10 weeks; 25-35 g)[1] Doses: 10 mg/kg, co-incubation with Paxalisib Route of Administration: Intraperitoneal injection (i.p.); once daily for 4 weeks Experimental Results: Markedly reduced tumor size to an isolated nest of HA-positive cells and prolonged survival rate. |
| References |
| Molecular Formula |
C22H19N3O2
|
|---|---|
| Molecular Weight |
357.41
|
| CAS # |
2404652-80-6
|
| Related CAS # |
MT-125
|
| Appearance |
Light yellow to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7979 mL | 13.9895 mL | 27.9791 mL | |
| 5 mM | 0.5596 mL | 2.7979 mL | 5.5958 mL | |
| 10 mM | 0.2798 mL | 1.3990 mL | 2.7979 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
